Specialized Hospital For Rehabilitation Health EAD
- Address
- Ulitsa Georgi S.Rakovski 15, 1320 Bankya, Bulgaria
Specialized Hospital For Rehabilitation Health EAD - Chronic Kidney Disease Research
The Specialized Hospital For Rehabilitation Health EAD is engaged in advanced clinical research focusing on chronic kidney disease management and rehabilitation. The center specializes in investigating novel therapeutic approaches for patients with kidney damage, particularly exploring the intersection of metabolic conditions and renal disease progression.
- Chronic kidney disease treatment and dose-response studies
- Kidney damage biomarkers and urinary albumin-to-creatinine ratio (UACR) reduction
- Management of renal complications in patients with type 2 diabetes and obesity
The center's research program emphasizes the characterization of dose-response relationships for emerging pharmacological interventions targeting kidney damage reduction. Their work addresses the critical need for effective treatments in patients with chronic kidney disease, whether occurring independently or in association with type 2 diabetes and obesity, contributing to improved rehabilitation outcomes and quality of life for individuals with complex metabolic and renal conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specialized Hospital For Rehabilitation Health EAD
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Cardiovascular Safety of Cagrilintide and Semaglutide in Participants with Established Cardiovascular Disease | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2023 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 2 | Unknown | 2023-02-28 | 2025-04-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.